Agreement - December 21, 2020
Nanoform and Herantis sign a letter of intent to collaborate
Nanoform Finland and Herantis Pharma have signed a letter of intent to collaborate to seek to enhance nasal drug delivery to the brain of Herantis’ CDNF and xCDNF therapies (Parkinson’s disease) using Nanoform’s biological nanoparticle technology. The planned and non-exclusive collaboration is intended to assess the utility of Nanoform’s latest platform technology for biologic drugs. […]
Clinical Trials - September 1, 2020
Herantis Pharma announces Phase I-II study results
Herantis Pharma has announced that its novel drug candidate, Cerebral Dopamine Neurotrophic Factor (CDNF) for the treatment of Parkinson’s disease (PD), has successfully achieved its primary endpoint of safety and tolerability in a 12 month Phase I-II study in patients with moderate disease. CDNF is a multi- modal, natural protein that has shown potential to […]
Clinical Trials - March 2, 2020
Positive results from Herantis Pharma
Herantis Pharma has announced the results from the ongoing Phase 1-2 clinical trial examining its neuroprotective factor and novel drug candidate, CDNF, in patients with Parkinson’s disease. Herantis is developing CDNF as a disease-modifying treatment. As a novel neuroprotective and neurorestorative factor, CDNF acts on several mechanisms relevant to Parkinson’s disease and has been shown […]
Listing - January 9, 2020
Herantis Pharma has completed an upsized directed share issue and listing on the Swedish First North Growth Market
This dual listing will further enable the advance its two innovative programs: CDNF in Parkinson’s Disease and drug candidate, Lymfactin, in Lymphedema. As part of the offering Herantis issued a total of 618,018 new shares at a price of €6.72 EUR / SEK 71 per share bringing the total number of shares in the Company […]
Business article - April 15, 2019
Business Q&A: Herantis Pharma
We asked the CEO of Herantis Pharma, Pekka Simula, about what is in their pipeline right now, about their strategy to reach market and about patient-driven innovation. Herantis Pharma was created by a merger of two pharma companies, Hermo Pharma and Laurantis Pharma. It has a broad product portfolio in various therapeutic areas and several […]
Financing - March 13, 2019
Herantis Pharma raises 5.8 million EUR
The Finnish biotech company has announced a positive outcome of a directed share issue, gaining additional support from long-term strategic institutional investors. The share capital will not be increased. Instead, the entire subscription price of EUR 5,782,306.40 will be recorded in the invested unrestricted equity reserve of the company. As a result of the share […]
